Alphatec Holdings Inc Dossier - Source-backed chat

Alphatec Holdings Inc

ATECNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)0.91

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.32Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.6B

Enterprise Value $2.1B

Shares Outstanding 157.1M diluted

Moat Rating None

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alphatec Holdings (ATEC) presents a compelling high-growth opportunity in the spine surgery market, trading at a significant discount following a Q1 2026 sell-off. While execution issues in the capital-intensive EOS imaging segment led to a top-line miss and guidance cut, the core surgical business remains exceptionally strong. Surgical revenue grew 17% year-over-year in Q1 2026, driven by a 21% surge in procedure volume and a 23% increase in new surgeon adoption. Furthermore, ATEC's financial risk profile has dramatically improved following a comprehensive debt refinancing led by JPMorgan Chase, which extends maturities to 2031 and reduces annual interest expenses by over $6 million. With a clear path to generating at least $20 million in free cash flow for FY 2026 and turning profitable by 2028, the current valuation represents an attractive entry point for long-term investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$15.79

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.00

The bear case reflects prolonged execution headwinds in the EOS segment, pricing pressure on surgical procedures (as seen in the 3% decline in revenue per case in Q1 2026), and failure to scale international operations. High leverage remains a drag if free cash flow generation falls short of the $20 million target, delaying the path to profitability.

Base CaseCentral scenario

$15.79

Matches the consensus mean

The base case projects that ATEC successfully delivers on its revised FY 2026 guidance of $882 million in total revenue (representing 15% growth), driven by $805 million in surgical revenue and a stabilized EOS segment at $77 million. Adjusted EBITDA reaches the guided $134 million (15% margin) with positive free cash flow of at least $20 million, supported by $6 million in interest savings from the refinanced credit facility.

Bull CaseUpside scenario

$24.00

The bull case assumes rapid recovery in the EOS segment driven by newly added sales talent, combined with accelerated adoption of the proprietary Valence workflow platform and OsteoAdapt biologic. Surgical revenue growth exceeds high-teens guidance, operating leverage drives EBITDA margins past 15%, and the company achieves GAAP profitability ahead of the 2028 consensus.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Robust volume-driven growth in the core surgical business, with Q1 2026 procedure volume up 21% and new surgeon users up 23%.
Strategic debt refinancing with a JPMorgan-led syndicated bank facility, reducing annual interest expenses by over $6 million and extending maturities to 2031.
Strong alignment of insider incentives, highlighted by Director Keith Valentine's substantial purchase of 135,000 shares in May 2026 following the post-earnings stock drop.
Clear visibility toward positive free cash flow of at least $20 million in FY 2026 and consensus-backed profitability by 2028.

Key Investment Risks

Execution risk in the capital-intensive EOS imaging segment, which underperformed in Q1 2026 and forced a downward revision in full-year revenue guidance.
High leverage and debt load, carrying over $600 million in total debt, which requires disciplined cash flow management to avoid covenant or liquidity pressures.
Procedural pricing headwinds, as average revenue per surgical case declined by approximately 3% year-over-year in Q1 2026.
Intense competition from larger, well-capitalized medtech conglomerates such as Globus Medical (post-NuVasive merger), Medtronic, and Stryker.

Thesis Invalidation Triggers

Failure to achieve positive free cash flow for the full year 2026.
Further downward revisions to FY 2026 revenue or adjusted EBITDA guidance.
A sustained decline in new surgeon adoption rates or surgical case volumes below double-digit growth.
Material regulatory delays or clinical trial setbacks for key pipeline products like OsteoAdapt.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.